Tagged: trial RSS Toggle Comment Threads | Keyboard Shortcuts

  • NoCamels Team 11:11 am on March 18, 2013 Permalink | Reply
    Tags: , , , trial   

    BioCancell Reports Success On Bladder Cancer Study 

    BioCancell Reports Success On Bladder Cancer Study Israeli cancer treatment developer BioCancell has achieved successful results on 64 percent of patients treated for bladder cancer. The company tested its BC-819 treatment, which is intended for patients that cannot be treated with chemotherapy or Bacillus Calmette-Guerin (BCG). Out of 39 patients treated, cancer was eradicated in 25 and the patients did not develop new tumors over the three-month trial period.

     
  • NoCamels Team 9:12 pm on February 5, 2013 Permalink | Reply
    Tags: bc-819, , , positive, results, trial   

    BioCancell Reports Positive Results On Pancreatic Cancer Treatment 

    BioCancell Reports Positive Results On Pancreatic Cancer TreatmentIsraeli company BioCancell Therapeutics Ltd., has announced positive results in a Phase IIb clinical trial of its BC-819 treatment for pancreatic cancer. The study showed that the drug is safe for all patients and that increasing the dosage of the drug does not cause deterioration in the patients’ condition.

     
  • NoCamels Team 5:17 pm on February 5, 2013 Permalink | Reply
    Tags: , , clinical, , trial   

    First Pateinet Begins Treatment With BrainStorm’s ALS Therapy 

    First Pateinet Begins Treatment With BrainStorm's ALS TherapyBrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, has announced that the first patient began treatment in the Company’s Phase IIa dose-escalating clinical trial for ALS. The trial, which will evaluate the safety and preliminary efficacy of BrainStorm’s NurOwn stem cell therapy candidate, is being conducted at the Hadassah Medical Center in Jerusalem.

     
  • NoCamels Team 11:38 am on January 29, 2013 Permalink | Reply
    Tags: , , schizophrenia, , trial   

    Pharmaceutical Company BiolineRX To Raise $15M 

    Pharmaceutical Company BiolineRX To Raise $15MIsraeli company BiolineRX, which is currently testing an innovative drug for treating schizophrenia, is planning a financing round, with a $15 million goal. “Calcalist” reports that the round is set to take place before the interim analysis of the clinical trial planned in March.

     
  • NoCamels Team 1:22 pm on January 27, 2013 Permalink | Reply
    Tags: , , , , , trial   

    Brainsway Trial Shows Significant Results For Smoking Addiction Treatment 

    Brainsway Trial Shows Significant Results For Smoking Addiction TreatmentIsraeli company Brainsway, which developed a device called Deep TMS (transcranial magnetic stimulation), for treating various brain-related disorders, has announced a successful trial of its treatment for smoking addiction. 84 percent of subjects in the trial quit smoking after receiving the treatment, of which approx. one-third were still non-smokers after a six month period.

     
  • NoCamels Team 1:09 pm on December 26, 2012 Permalink | Reply
    Tags: cervical cancer, , , trial   

    Micromedic Reports Positive Results On Cancer Detection Trial 

    Micromedic Reports Positive Results On Cancer Detection TrialIsraeli medical diagnostic technology developer Micromedic Technologies Ltd., has announced positive intermediary results in its trial of CellDetect, a technology for detecting cervical cancer. The results show a 94 percent success rate. In light of these results, Micromedic’s share price rose 10.48 percent.

     
  • NoCamels Team 2:37 pm on December 4, 2012 Permalink | Reply
    Tags: biocontrol medical, , implant, , trial   

    BioControl Reports Positive Results On Early Stage Epilepsy Treatment Trial 

    BioControl Reports Positive Results On Early Stage Epilepsy Treatment TrialIsraeli company BioControl Medical, which develops implant for treating complex medical conditions, has reported positive results on its FitNeS treatment trial. The device was implanted in five patients, all of which shown a reduction of up to 50 percent in seizures and no side effects.

     
  • NoCamels Team 7:53 am on June 4, 2012 Permalink | Reply
    Tags: , , Rituxan, Roche, , Treanda, trial,   

    ‘Teva’: Positive Results For Lymphoma Treatment Trial 

    Teva - News Flash - IsraelTeva Pharmaceutical Industries announced positive results for its Treanda drug trial, for the treatment of lymphoma. During the trial, Treanda was given to patients with slow-growing lymphoma (non-Hodgkin lymphoma), in combination with Roche’s Rituxan. Results showed that patients treated with the combined drugs lived three years longer with no progression of their tumors, compared to those taking chemotherapy with Rituxan.

     
  • NoCamels Team 3:05 pm on May 7, 2012 Permalink | Reply
    Tags: hGH-CTP, , Phase II, , trial   

    ‘Prolor’: Positive Results In Human Growth Hormone Trial 

    Prolor - News Flash - IsraelProlor Biotech reported positive results from a Phase II four-month treatment extension study of hGH-CTP, its long-acting version of human growth hormone, in growth hormone deficient adults. The findings show that a single weekly injection of hGH-CTP has the potential to replace seven consecutive daily injections of currently marketed human growth hormone (hGH), and further validates the dosing regimen for the company’s planned Phase III trial. In the Phase II clinical trial, hGH-CTP was administered to growth hormone deficient adults for a period of four weeks.

     
  • NoCamels Team 5:04 am on April 22, 2012 Permalink | Reply
    Tags: , European Commission, , , trial   

    Israeli Co Produces Human Growth Hormone From Algae 

    Rosetta-Green - News Flash - IsraelRosetta Green, an Israeli company which specializes in crop improvement for the agriculture and alternative fuel industries, announced it has successfully completed an experiment producing human growth hormone from algae. The project is part of the European Commission’s effort to manufacture chemicals and proteins in algae, at an estimated $7 million. It is managed by Professor Sammy Boussiba from Ben Gurion University of the Negev. According to the company, it intends to further test these human proteins in clinical trials in mice.

     
c
compose new post
j
next post/next comment
k
previous post/previous comment
r
reply
e
edit
o
show/hide comments
t
go to top
l
go to login
h
show/hide help
shift + esc
cancel